Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions

References

• Torres J, Mehandru S, Colombel J-F, et al. Crohn’s disease. Lancet. 2017;389:1741–1755.
   PubMed Web of Science ®Google Scholar
• Colìa R, Corrado A, Cantatore FP. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases. Ann Med. 2016;48(2016):577–585.
   PubMedGoogle Scholar
• Chang MI, Cohen BL, Greenstein AJ. A review of the impact of biologics on surgical complications in Crohn’s disease. Inflamm Bowel Dis. 2015;21:1472–1477.
   PubMed Web of Science ®Google Scholar
• Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239–254.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Vlachonikolis, DM, van der Heijde, G Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36:1307–1313.
   PubMed Web of Science ®Google Scholar
• Stolwijk C, Pierik M, Landew_e R, et al. Prevalence of self-reported spondyloarthritis features in a cohort of patients with inflammatory bowel disease. Can J Gastroenterol. 2013;27:199–205.
   PubMed Web of Science ®Google Scholar
• Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585–595.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Cantini F, Castiglione F, et al. Italian expert panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev. 2014;13:822–830.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135–149.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–991.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol. 2009;15:2449–2455.
   PubMed Web of Science ®Google Scholar
• Argollo M, Fiorino G, Peyrin-Biroulet L, et al. Vedolizumab for the treatment of Crohn’s disease. Expert Rev Clin Immunol. 2018;14:179–189.
   PubMed Web of Science ®Google Scholar
• Tadbiri S, Peyrin-Biroulet L, Serrero M, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47:485–493.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Orlando R, Fries W, et al. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis. 2018;50:675–681.
   PubMedGoogle Scholar
• Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 2017;76:878–881.
   PubMed Web of Science ®Google Scholar
• Wendling D, Sondag M, Verhoeven F, et al. Arthritis occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease . Joint Bone Spine. 2018;85:255–256.
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm Bowel Dis. 1998;4:149–156.
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol. 2001;166:4650–4657.
   PubMed Web of Science ®Google Scholar
• Tahir H. Therapies in ankylosing spondylitis – from clinical trials to clinical practice. Rheumatology (Oxford). 2018;57(suppl_6):vi23–vi28.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–1071.
   PubMed Web of Science ®Google Scholar
• Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008;87:281–293.
   PubMed Web of Science ®Google Scholar
• Phillips FM, Verstockt B, Sebastian S, et al. Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multi-centre case series. J Crohns Colitis. 2019;13(Suppl_1):S292–S293.
   Google Scholar
• Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–119.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Gubler M, Gantenbein C, et al. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the swiss IBD Cohort study. Inflamm Bowel Dis. 2017;23:1174–1181.
   PubMed Web of Science ®Google Scholar
• Löfberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: results from CARE. Inflamm Bowel Dis. 2012;18:1–9.
   PubMed Web of Science ®Google Scholar
• Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, et al. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol. 2007;21:408–410.
   PubMed Web of Science ®Google Scholar
• Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allerg Immunol. 2017;53:413–427.
   PubMed Web of Science ®Google Scholar
• Fonder MA, Cummins DL, Ehst BD, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006;5:e8.
   PubMedGoogle Scholar
• Brooklyn TN, Dunnill MG, Shetty A. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–509.
   PubMed Web of Science ®Google Scholar
• Zampeli VA, Lippert U, Nikolakis G, et al. Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. J Dermatol Case Rep. 2015;9:62–66.
   PubMed Web of Science ®Google Scholar
• Hurabielle C, Schneider P, Baudry C, et al. Certolizumab pegol – a new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease. J Dermatolog Treat. 2016;27:67–69.
   PubMed Web of Science ®Google Scholar
• Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147:1203–1205.
   PubMedGoogle Scholar
• Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67:e237–238.
   PubMed Web of Science ®Google Scholar
• Fahmy M, Ramamoorthy S, Hata T, et al. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012;107:794–795.
   PubMed Web of Science ®Google Scholar
• Greb JE, Gottlieb AB, Goldminz AM. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol Ther. 2016;29:482–483.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185–196.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population based study. Am J Gastroenterol. 2001;96:1116–1122.
   PubMed Web of Science ®Google Scholar
• Fries W, Giofré MR, Catanoso M, et al. Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. Am J Gastroenterol. 2002;97:499–500.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352–356.
   PubMed Web of Science ®Google Scholar
• Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:1424–1429.
   PubMed Web of Science ®Google Scholar
• Ally MR, Veerappan GR, Koff JM. Treatment of recurrent Crohn’s uveitis with infliximab. Am J Gastroenterol. 2008;103:2150–2151.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932–943.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–1192.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Del Piano M, et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017;30:5.
   Web of Science ®Google Scholar
• Pepple KL, Lin P. Targeting interleukin-23 in the treatment of noninfectious uveitis. Ophthalmology. 2018;125:1977–1983.
   PubMed Web of Science ®Google Scholar
• Arepalli S, Rosenbaum JT. The use of biologics for uveitis associated with spondyloarthritis. Curr Opin Rheumatol. 2019;31:349–354.
   PubMed Web of Science ®Google Scholar
• Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26:31–41.
   PubMed Web of Science ®Google Scholar
• Venkatesh PG, Navaneethan U, Shen B. Hepatobiliary disorders and complications of inflammatory bowel disease. J Dig Dis. 2011;12:245–256.
   PubMed Web of Science ®Google Scholar
• Bo X, Broome U, Remberger M, et al. Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut. 2001;49:131–141.
   PubMed Web of Science ®Google Scholar
• Liaskou E, Jeffery LE, Trivedi PJ, et al. Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterology. 2014;147:221–232.e7.
   PubMed Web of Science ®Google Scholar
• Tse CS, Loftus.EV J, Raffals LE, et al. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48:190–195.
   PubMed Web of Science ®Google Scholar
• Franceschet I, Cazzagon N, Del Ross T, et al. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. Eur J Gastroenterol Hepatol. 2016;28:508–513.
   PubMed Web of Science ®Google Scholar
• Halilbasic E, Fuchs C, Hofer H, et al. Therapy of primary sclerosing cholangitis – today and tomorrow. Dig Dis. 2015;33(Suppl 2):149–163.
   PubMedGoogle Scholar
• Stine JG, Wang J, Behm BW. Chronic cholestatic liver injury attributable to vedolizumab. J Clin Transl Hepatol. 2016;4:277–280.
   PubMed Web of Science ®Google Scholar
• Lynch KD, Keshav S, Chapman RW. The use of biologics in patients with inflammatory bowel disease and primary sclerosing cholangitis. Curr Hepatol Rep. 2019;18:115–126.
   PubMedGoogle Scholar
• Vegh Z, Macsai E, Lakatos L, et al. The incidence of glomerulonephritis in a population-based inception cohort of patients with inflammatory bowel disease. Dig Liver Dis. 2017;49:718–719.
   PubMedGoogle Scholar
• Ambruzs JM, Larsen CP. Renal manifestations of inflammatory bowel disease. Rheum Dis Clin North Am. 2018;44:699–714.
   PubMed Web of Science ®Google Scholar
• Oikonomou K, Kapsoritakis A, Eleftheriadis T, et al. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1034–1045.
   PubMed Web of Science ®Google Scholar
• Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn’s disease treated with infliximab. Inflamm Bowel Dis. 2008;14:431–432.
   PubMed Web of Science ®Google Scholar
• Said Y, Debbeche R, Hamzaoui L, et al. Infiximab for treatment of systemic amyloidosis associated with Crohn’s disease. J Crohns Colitis. 2011;5:171–172.
   PubMed Web of Science ®Google Scholar
• Iizuka M, Sagara S, Etou T. Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with Crohn’s disease. Inflamm Bowel Dis. 2011;17:E67–68.
   PubMedGoogle Scholar
• Pukitis A, Zake T, Groma V, et al. Effect of infliximab induction therapy on secondary systemic amyloidosis associated with Crohn’s disease: case report and review of the literature. J Gastrointestin Liver Dis. 2013;22:333–336.
   PubMed Web of Science ®Google Scholar
• Tosca Cuquerella J, Bosca-Watts MM, Anton Ausejo R, et al. Amyloidosis in inflammatory bowel disease: a systematic review of epidemiology, clinical features, and treatment. J Crohns Colitis. 2016;10:1245–1253.
   PubMed Web of Science ®Google Scholar
• Esatoglu SN, Hatemi G, Ugurlu S, et al. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: a STROBE-compliant observational study. Medicine (Baltimore). 2017;96:e7859.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar N, Loftus.EV J, et al. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis. 2013;19:864–872.
   PubMed Web of Science ®Google Scholar
• Zois CD, Katsanos KH, Kosmidou M, et al. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J Crohns Colitis. 2010;4:115–124.
   PubMed Web of Science ®Google Scholar
• Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281–292.
   PubMed Web of Science ®Google Scholar
• Burger DC, Florin TH. Peripheral neuropathy with infliximab therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1772.
   PubMed Web of Science ®Google Scholar
• Cesarini M, Angelucci E, Foglietta T, et al. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn’s disease patient: case report and literature review. J Crohns Colitis. 2011;5:619–622.
   PubMed Web of Science ®Google Scholar
• Tsouni P, Bill O, Truffert A, et al. Anti-TNF alpha medications and neuropathy. J Peripher Nerv Syst. 2015;20:397–402.
   PubMed Web of Science ®Google Scholar
• Yagita M, Hamano T, Hatachi S, et al. Peripheral neuropathies during biologic therapies. Mod Rheumatol. 2016;26:288–293.
   PubMed Web of Science ®Google Scholar
• Rodinò S, Saccà N, D’Amico T, et al. Severe polyneuropathy complicating active Crohn’s disease: rapid response to Infliximab. Gut. 2003;52:1070.
   PubMed Web of Science ®Google Scholar
• Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17:36.
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7:796–804.
   PubMed Web of Science ®Google Scholar
• Gensicke H, Leppert D, Ö Y, et al. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs. 2012;26:11–37.
   PubMed Web of Science ®Google Scholar
• Moran GW, Dubeau MF, Kaplan GG, et al. The increasing weight of Crohn’s disease subjects in clinical trials: a hypothesis-generating time-trend analysis. Inflamm Bowel Dis. 2013;19:2949–2956.
   PubMed Web of Science ®Google Scholar
• Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2118–2124.
   PubMed Web of Science ®Google Scholar
• Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine. 2019;86:173–183.
   PubMed Web of Science ®Google Scholar
• Ding Z, Wu XR, Remer EM, et al. Association between high visceral fat area and postoperative complications in patients with Crohn’s disease following primary surgery. Colorectal Dis. 2016;18:163–172.
   PubMed Web of Science ®Google Scholar
• Gremese E, Carletto A, Padovan M, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res. 2013;65:94–100.
   PubMed Web of Science ®Google Scholar
• Hemperly A, Vande Casteele N. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57:929–942.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Baert F, Bian S, et al. Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn’s disease: a prospective multicentre study. J Crohns Colitis 2019;13:1248–1256.
   Google Scholar
• Guerbau L, Gerard R, Duveau N, et al. Patients with Crohn’s disease with high body mass index present more frequent and rapid loss of response to infliximab. Inflamm Bowel Dis. 2017;23:1853–1859.
   PubMed Web of Science ®Google Scholar
• Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25:1007–1011.
   PubMed Web of Science ®Google Scholar
• Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology. 2015;230:46–54.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63:571–579.
   PubMed Web of Science ®Google Scholar
• Del Alcázar E, Ferran M, López-Ferrer A, et al. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. J Dermatolog Treat. 2019;1–5.
   PubMedGoogle Scholar
• Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohns Colitis. 2019. DOI:10.1093/ecco-jcc/jjz162
   Google Scholar
• Kurnool S, Nguyen NH, Proudfoot J, et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018;47:1472–1479.
   PubMed Web of Science ®Google Scholar
• Ward MG, Sparrow MP, Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therap Adv Gastroenterol. 2018;11:1756284818772786.
   Web of Science ®Google Scholar
• Li H, Shi FH, Huang SY, et al. A review on clinical pharmacokinetics, pharmacodynamics, and pharmacogenomics of natalizumab: a humanized anti-α4 integrin monoclonal antibody. Curr Drug Metab. 2018;19:1213–1223.
   PubMed Web of Science ®Google Scholar
• Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72:402–409.
   PubMed Web of Science ®Google Scholar
• Nelson SM, Nguyen TM, McDonald JW, et al. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;8:CD006097.
   PubMedGoogle Scholar
• Zou ZY, Shen B, Fan JG. Systematic review with meta-analysis: epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:1764–1772. DOI:10.1093/ibd/izz043
   Web of Science ®Google Scholar
• Liu W, Baker RD, Bhatia T, et al. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73:1969–1987.
   PubMed Web of Science ®Google Scholar
• Koca SS, Bahcecioglu IH, Poyrazoglu OK, et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation. 2008;31:91–98.
   PubMed Web of Science ®Google Scholar
• Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008;46:1369–1371.
   PubMed Web of Science ®Google Scholar
• Jess T, Jensen BW, Andersson M, et al., Inflammatory bowel disease increases risk of type 2 diabetes in a nationwide cohort study. Clin Gastroenterol Hepatol. 2019;19:S1542–3565(19)30841-9. DOI:10.1016/j.cgh.2019.07.052
   Google Scholar
• Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp. 2013;61:119–125.
   PubMed Web of Science ®Google Scholar
• Araújo EP, De Souza CT, Ueno M, et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology. 2007;148:5991–5997.
   PubMed Web of Science ®Google Scholar
• Yazdani-Biuki B, Stelzl H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest. 2004;34:641–642.
   PubMed Web of Science ®Google Scholar
• Gupta-Ganguli M, Cox K, Means B, et al. Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care. 2011;34:e121.
   PubMedGoogle Scholar
• Yazdani-Biuki B, Mueller T, Brezinschek HP, et al. Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation. Diabetes Care. 2006;29:1712–1713.
   PubMed Web of Science ®Google Scholar
• Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2015;24:283–307.
   PubMed Web of Science ®Google Scholar
• Marwaha AK, Tan S, Dutz JP. Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes. Clin Immunol. 2014;154:84–89.
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, et al. Anti-TNF therapy against congestive heart failure investigators. randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133–3140.
   PubMed Web of Science ®Google Scholar
• Tam LS, Kitas GD, González-Gay MA. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford). 2014;53:1108–1119.
   PubMed Web of Science ®Google Scholar
• van Sijl AM, van Eijk IC, Peters MJ, et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:119–123.
   PubMed Web of Science ®Google Scholar
• Sanjadi M, Rezvanie Sichanie Z, Totonchi H, et al. Atherosclerosis and autoimmunity: a growing relationship. Int J Rheum Dis. 2018;21:908–921.
   PubMed Web of Science ®Google Scholar
• Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636–647.
   PubMed Web of Science ®Google Scholar
• Halling ML, Kjeldsen J, Knudsen T, et al. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol. 2017;23:6137–6146.
   PubMed Web of Science ®Google Scholar
• Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013;13:1715–1730.
   PubMed Web of Science ®Google Scholar
• Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54:102–113.
   PubMed Web of Science ®Google Scholar
• Shah VV, Lee EB, Reddy S, et al. Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review. J Dermatolog Treat. 2018;29:586–592.
   PubMed Web of Science ®Google Scholar
• Frieder J, Kivelevitch D, Fiore CT, et al. The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. Expert Rev Clin Immunol. 2018;14:1–19.
   PubMed Web of Science ®Google Scholar
• Thibodaux RJ, Triche MW, Espinoza LR. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review. Expert Opin Biol Ther. 2018;18:821–827.
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American college of rheumatology/National psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5–32.
   PubMed Web of Science ®Google Scholar
• Barthel C, Biedermann L, Frei P, et al. Induction or exacerbation of psoriasis in patients with Crohn’s disease under treatment with anti-TNF antibodies. Digestion. 2014;89:209–215.
   PubMed Web of Science ®Google Scholar
• Santos S, Gamelas V, Carvalho D, et al. Therapeutic strategies in the approach of paradoxical psoriasis in IBD: experience of a centre. J Crohns Colitis. 2019;13(Suppl_1):S403–S404.
   Google Scholar
• Shah ED, Farida JP, Siegel CA, et al. Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-analysis. Inflamm Bowel Dis. 2017;23:570–577.
   PubMed Web of Science ®Google Scholar
• McConnell RA, Mahadevan U. Pregnancy and the patient with inflammatory bowel disease: fertility, treatment, delivery, and complications. Gastroenterol Clin North Am. 2016;45:285–301.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377–1385.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Mahadevan U, et al. Pregnancy outcomes reported during the 13-year TREAT registry: a descriptive report. Am J Gastroenterol. 2018;113:1678–1688.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol. 2018;113:396–403.
   PubMed Web of Science ®Google Scholar
• Porter C, Armstrong-Fisher S, Kopotsha T, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016;116:7–12.
   PubMed Web of Science ®Google Scholar
• Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228–233.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Wolf DC, Förger F, et al. Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol. 2015;42:2270–2278.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018;70:1399–1407.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890–1896.
   PubMed Web of Science ®Google Scholar
• Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2017;42:234–236.
   PubMed Web of Science ®Google Scholar
• Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohns Colitis. 2018;12:376–378.
   PubMed Web of Science ®Google Scholar
• Wieringa JW, Driessen GJ. Van Der Woude CJ. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Expert Rev Gastroenterol Hepatol. 2018;12:811–818.
   PubMed Web of Science ®Google Scholar
• Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
   PubMed Web of Science ®Google Scholar
• AlAmeel T, Al Sulais E. Ustekinumab and pregnancy: continue or cease before you conceive? Gastroenterology. 2019. DOI:10.1053/j.gastro.2019.05.077
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Kjeldsen J, Baumgart DC. Vedolizumab safety in pregnancy and newborn outcomes. Gut. 2017;66:1866–1867.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:941–950.
   PubMed Web of Science ®Google Scholar
• Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, et al. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol. 2019;114:1172–1175.
   PubMed Web of Science ®Google Scholar
• Moens A, van der Woude C, Julsgaard M M, et al. Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF, or conventional therapy. J Crohns Colitis. 2019;13(Suppl_1):S041–S042.
   Google Scholar
• Moens A, van Hoeve K, Humblet E, et al. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. J Crohns Colitis. 2019;13:12–18.
   PubMed Web of Science ®Google Scholar
• Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis Organisation topical review on IBD in the elderly. J Crohns Colitis. 2017;11:263–273.
   PubMed Web of Science ®Google Scholar
• Jeuring SF, van den Heuvel TR, Zeegers MP, et al. Epidemiology and longterm outcome of inflammatory bowel disease diagnosed at elderly age – an increasing distinct entity? Inflamm Bowel Dis. 2016;22:1425–1434.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Sheng L, Benchimol EI. Health care utilization in elderly onset inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 2015;21:777–782.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:107–112.
   PubMed Web of Science ®Google Scholar
• Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–35.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Umezawa Y, Fukuchi O, et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41:974–980.
   PubMed Web of Science ®Google Scholar
• Pudipeddi A, Kariyawasam V, Haifer C, et al. Safety of drugs used for the treatment of Crohn’s disease. Expert Opin Drug Saf. 2019;18:357–367.
   PubMed Web of Science ®Google Scholar
• McLean LP, Cross RK. Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease. Expert Opin Investig Drugs. 2016;25:263–273.
   PubMed Web of Science ®Google Scholar
• Boland BS, Vermeire S. Janus kinase antagonists and other novel small molecules for the treatment of Crohn’s disease. Gastroenterol Clin North Am. 2017;46:627–644.
   PubMed Web of Science ®Google Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2016;66:199–209.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–275.
   PubMed Web of Science ®Google Scholar
• Hirten R, Longman RS, Bosworth BP, et al. Vedolizumab and infliximab combination therapy in the treatment of Crohn’s disease. Am J Gastroenterol. 2015;110:1737–1738.
   PubMed Web of Science ®Google Scholar
• Yzet C, Dupas JL, Fumery M. Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease. Am J Gastroenterol. 2016;111:748–749.
   PubMed Web of Science ®Google Scholar
• Fischer S, Rath T, Geppert CI, et al. Long-term combination therapy with anti-TNF plus vedolizumab induces and maintains remission in therapy-refractory ulcerative colitis. Am J Gastroenterol. 2017;112:1621–1623.
   PubMed Web of Science ®Google Scholar
• Bethge J, Meffert S, Ellrichmann M, et al. Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. BMJ Open Gastroenterol. 2017;4:e000127.
   PubMed Web of Science ®Google Scholar
• Mao EJ, Lewin S, Terdiman JP, et al. Safety of dual biological therapy in Crohn’s disease: a case series of vedolizumab in combination with other biologics. BMJ Open Gastroenterol. 2018;5:e000243.
   PubMed Web of Science ®Google Scholar
• Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007;13:2–11.
   PubMed Web of Science ®Google Scholar
• Hirten RP, Iacucci M, Shah S, et al. Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. Clin Gastroenterol Hepatol. 2018;16:1374–1384.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Clinical usefulness of proteomics in inflammatory bowel disease: a comprehensive review. J Crohns Colitis. 2019;13:374–384.
   PubMed Web of Science ®Google Scholar
• Atreya R, Neumann H, Neufert C, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med. 2014;20:313–318.
   PubMed Web of Science ®Google Scholar
• Reinglas J, Gonczi L, Kurt Z, et al. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol. 2018;24:3567–3582.
   PubMed Web of Science ®Google Scholar